 An online sample of 600 American participants was recruited from Amazons Mechanical Turk. Respondents were randomly assigned to 5 conditions in which they read an excerpt from a news article describing a newly FDA-approved fictionalized breakthrough therapy, Zykanta, for treating metastatic lung cancer. Information on this fictionalized drug was drawn from a real-life breakthrough designated drug so as to be able to provide as accurate an example as possible with respect to inherent uncertainty in risk and benefit. Each condition communicated information about Zykanta with a greater or lesser degree of transparency regarding the contingent nature of a breakthrough approved drug. All conditions contained the same factual information about the risks and benefits of the drug. In the first condition - a Purely Factual condition - participants read a clear and concise technical definition of breakthrough therapy designation about a drug that was approved 4 months ahead of schedule, without seeing the term breakthrough attached to the drug. This condition provides the basic risk-benefit information made available by the FDA without loaded terminology. In the second condition, the factual information was enhanced by describing the drug as Promising - the language the FDA uses in press releases about breakthrough drugs. This condition provides a more tempered label for this designation, but a label nonetheless. In the third condition, the factual information was enhanced by describing the drug as Breakthrough. In the fourth condition, factual information about the drug was enhanced by describing the drug as Breakthrough, but additionally contained a Tentative Disclaimer about the possible uncertainty surrounding the drug. This condition reflects the information found in the small print of the labeling of some breakthrough drugs. In the fifth condition, the factual drug information was enhanced by describing the drug as Breakthrough, but contained a more Definitive Disclaimer about the uncertainty surrounding the drug and its need for further testing. 